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Abstract
Recently, traditional Chinese medicine and medicinal herbs have attracted more attentions worldwide for its anti-tumor
efficacy. Celastrol and Triptolide, two active components extracted from the Chinese herb Tripterygium wilfordii Hook F
(known as Lei Gong Teng or Thunder of God Vine), have shown anti-tumor effects. Celastrol was identified as a natural 26 s
proteasome inhibitor which promotes cell apoptosis and inhibits tumor growth. The effect and mechanism of Triptolide on
prostate cancer (PCa) is not well studied. Here we demonstrated that Triptolide, more potent than Celastrol, inhibited cell
growth and induced cell death in LNCaP and PC-3 cell lines. Triptolide also significantly inhibited the xenografted PC-3
tumor growth in nude mice. Moreover, Triptolide induced PCa cell apoptosis through caspases activation and PARP
cleavage. Unbalance between SUMOylation and deSUMOylation was reported to play an important role in PCa progression.
SUMO-specific protease 1 (SENP1) was thought to be a potential marker and therapeutical target of PCa. Importantly, we
observed that Triptolide down-regulated SENP1 expression in both mRNA and protein levels in dose-dependent and time-
dependent manners, resulting in an enhanced cellular SUMOylation in PCa cells. Meanwhile, Triptolide decreased AR and c-
Jun expression at similar manners, and suppressed AR and c-Jun transcription activity. Furthermore, knockdown or ectopic
SENP1, c-Jun and AR expression in PCa cells inhibited the Triptolide anti-PCa effects. Taken together, our data suggest that
Triptolide is a natural compound with potential therapeutic value for PCa. Its anti-tumor activity may be attributed to
mechanisms involving down-regulation of SENP1 that restores SUMOylation and deSUMOyaltion balance and negative
regulation of AR and c-Jun expression that inhibits the AR and c-Jun mediated transcription in PCa.
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Introduction
The steady increase in the incidence and mortality rates of
cancers urges researchers to make great effort on searching for
novel anti-tumor drugs or therapies. Extracted compounds from
natural herbs, such as Taxol, have been widely used in cancer
therapy. Traditional Chinese medicine promises an important and
useful alternative in cancer treatment. Many active compounds
extracted from Chinese herbs have shown anti-tumor efficacy.
Triptolide and Celastrol, two active components extracted from
the Chinese herb Tripterygium wilfordii Hook F (known as Lei Gong
Teng or Thunder of God Vine) used for rheumatoid arthritis
therapy, have shown anti-tumor effect and apoptosis induction
[1,2]. Celastrol has been identified as a natural proteasome
inhibitor that causes the accumulation of ubiquitinated proteins
and proteasome substrates IkB-a, Bax, and p27. Celastrol also
induces apoptosis in PCa cells and shrinks the xenografted tumor
in mice [1]. Triptolide is a diterpene lactone with potent
immunosuppressive effects and anti-tumor properties in different
cancers, including melanoma [2], breast cancer [3], pancreatic
cancer [4], prostate cancer (PCa) [5] and others. Triptolide
induces cell apoptosis via inhibiting HSP70 in pancreatic cancer
cells [4,6], and interrupts the IL6R-JAK/STAT pathway in colon
cancer cells [7]. In human anaplastic thyroid carcinoma cells,
Triptolide significantly reduces the expression of the NF-kappa B
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and urokinase-type plasminogen activator [8]. Triptolide acts
either independently of or partly dependently on p53 to inhibit
solid xenografted tumors growth in mice [9,10]. However, the
efficacy and molecular mechanism of Triptolide on PCa are less
studied.
SUMOylation is a novel ubiquitin-like post-translational mod-
ification. Four different SUMO proteins, SUMO-1, SUMO-2,
SUMO-3 and SUMO-4, have been identified [11]. Similar to
ubiquitination, SUMOyaltion involves a series of enzymatic
processes. The mature SUMO is activated by conjugation to the
E1 enzyme (SAE1/SAE2), transferred to the E2 enzyme (Ubc9)
and ligated to the specific lysine residue of the target proteins by an
E3 enzyme [11]. SUMOylation modulates multiple cell biological
processes such as nuclear transport, cell cycle, chromatin
remodeling, transcriptional regulation, DNA repair, and altering
proteins ubiquitination and degradation [12]. Ample evidence has
shown that SUMOylation is involved in development of human
diseases including cancer.
SUMOylation is a reversible process. The conjugated SUMO
molecules can be cleaved by SUMO-specific proteases (SENPs).
Six SENP proteins have been identified which deSUMOylate
target proteins in different ways. SENP1 and SENP2 can remove
all 3 SUMOs from target proteins, whereas other SENPs show
specificity for SUMO-2 and SUMO-3 [13]. DeSUMOylation has
been demonstrated to involve in the human diseases progression
[14] such as PCa [15] and breast cancer [16]. Previously, Cheng et
al [15] reported that deSUMOylation plays an important role in
the development of PCa. They found that SENP1 was over-
expressed in human PCa specimens but not in normal human
prostate cells. siRNA inhibition of SENP1 reduced PCa cells
growth. In addition, their initial results in vivo in transgenic mice
indicated that over-expression of SENP1 leads to the development
of prostatic intraepithelial neoplasia (PIN) at an early age. Further,
SENP1 markedly enhances the activity of AR–dependent tran-
scription by deSUMOylation of HDAC1 [17] and c-Jun–
dependent transcription by deSUMOylating the CRD1 domain
of p300 [18], which all involved in the tumorigenesis of PCa.
Overall, these data suggest SENP1 play an important role in PCa
progression and could be a novel PCa marker and therapy target.
In the present study, we demonstrated that Triptolide signifi-
cantly inhibited PCa cell proliferation in vitro and xenografted PC-
3 tumor progression in vivo, Triptolide also induced apoptosis in
PCa cells. The anti-tumor efficacy of Triptolide was more potent
than Celastrol. Meanwhile, we found Triptolide significantly
down-regulated the SENP1 expression in both mRNA and protein
levels, resulting in an enhanced cellular SUMOylation in PCa
cells. Furthermore, Triptolide also negatively regulated AR and c-
Jun expression and suppressed AR and c-Jun transcription.
Overall, our experimental results suggest that Triptolide is a
natural potential compound for PCa therapy.
Results
Triptolide significantly inhibited PCa cell proliferation in
vitro
Both Triptolide (Fig. 1A) and Celastrol (Fig. 1B) belong to
terpenes and are two active components extracted from the
Chinese herb Tripterygium wilfordii Hook F [1,19]. Celastrol, as a
potent proteasome inhibitor, inhibits PCa cell proliferation and
induces cell apoptosis [1]. Triptolide has been reported to suppress
cell proliferation in many types of cancer, but its efficacy on PCa
and target molecules have not been clearly studied. To determine
the anti-tumor activity of Triptolide on PCa cells and compare
with Celastrol, we performed growth curve assay and cell viability
assay using two PCa cell lines, LNCaP (androgen-dependent) and
PC-3 cells (androgen-independent). We confirmed that both
Triptolide and Celastrol caused significant inhibition of prolifer-
ation in LNCaP and PC-3 cells. In the growth curve assay,
Triptolide significantly inhibited the proliferation of PCa cells even
at doses of 5 nM in LNCaP cells (Fig. 1C) and 10 nM in PC-3 cells
(Fig. 1E). In contrast, Celastrol only suppressed PCa cells growth
at high doses such as 1 mM in LNCaP cells (Fig. 1D) and 0.5 mM
in PC-3 cell (Fig. 1F). These results showed that Triptolide can
efficiently suppress PCa cell proliferation. To further determine
the cytotoxic effect of Triptolide on PCa cell and compare with
Celastrol, we carried out cell viability assay using MTT method.
Both PCa cell lines were treated with broad doses of Triptolide or
Celastrol, from 0.01 mMt o5 mM, for 48 h. As shown in
Figure 1G, at low dose (such as 0.02 mM), Triptolide was sufficient
to kill majority LNCaP cells but residual proportion of viable cells
persisted even in the presence of higher concentrations of
Triptolide. It was in contrast to the dose-dependent cytotoxic
effect of Celastrol. However, a much higher dose of Celastrol was
required to attain a similar cytotoxic effect with 0.02 mM
Triptolide. Similar pattern was observed in cell viability assay
for PC-3 cells (Fig. 1H). To quantify the efficacy of two
compounds on PCa cell, we calculated the IC50 value according
to the cell viability data. Triptolide had a much lower IC50 values
for both cell lines compared to Celastrol (Table 1). These data
demonstrated that Triptolide is an effective agent to inhibit PCa
cell proliferation and to induce cell death.
Triptolide induced apoptosis in PCa cells in vitro
We next assessed whether Triptolide- and Celastrol-induced cell
death corresponded to an apoptotic response. LNCaP and PC-3
cells were treated with 1 mM Triptolide and Celastrol for 24 h,
respectively, stained with fluorescein isothiocyanate (FITC)-con-
jugated annexin V (AV) and 50 mg/ml propidium iodide (PI), then
analyzed by fluorescence microscopy and by flow cytometry. The
simultaneous detection of phosphatidylserine externalization and
loss of membrane integrity with AV-FITC and PI, respectively,
discriminates between early apoptosis (AV+), late apoptosis
eventually leading to secondary necrosis (AV+/PI+) and primary
necrosis (PI+). As shown in Figure 2A and Figure 2B, treatment
with Triptolide and Celastrol resulted in a higher proportion of
cells with positive AV and/or PI staining. Flow cytometric analysis
showed that treatment with Triptolide and Celastrol caused
respectively 40% and 30% of LNCaP cells to be AV+/PI2,
whereas only ,6% of vehicle (DMSO)-treated cells showed an
apoptotic response. The two compounds had relatively moderate
effect in inducing apoptosis in PC-3 cells, 8.77% and 15.2%
respectively, versus 4% in vehicle (DMSO)-treated cells (Fig. 2C
and Fig. S1). These results showed that both Triptolide and
Celastrol induced apoptosis in PCa cells. In addition, LNCaP cells
were more sensitive to Triptolide and Celastrol than PC-3 cells. It
has been reported that Triptolide induces apoptosis through
caspase cascade [4–6]. To further determine whether caspase is
involved in Triptolide-induced apoptosis in PCa cells, we
investigated the status of caspase-3 in PCa cells treated with
various doses Triptolide or Celastrol for 24 h or with 1 mM
Triptolide and Celastrol for desired times. Activation of caspases-3
was monitored by Western blot using a polyclonal antibody that
recognize both procaspase-3 and its active cleavage fragments, p17
and p12. As shown in Figure 2D–2E, the cleavage of procaspase-3
was enhanced in Triptolide-treated LNCaP cells, and to a less
degree, in Celastrol-treated LNCaP cells. Only very low levels of
caspase-3 fragments were detectable in Celastrol or Triptolide-
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37693Figure 1. Triptolide and Celastrol inhibited cell growth and induced cell death in PCa cell lines. (A) and (B) The chemical structure of
Triptolide (A) and Celastrol (B), respectively. (C), (D), (E) and (F) PCa cells were treated with indicated doses of Triptolide or Celastrol, viable cell
numbers were counted every day for 6 days. All assays were performed in triplicate, and data shown are mean 6 SD of three independent
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poly (ADP-ribose) polymerase (PARP) that is one of the main
cleavage targets of Caspase-3. PARP cleavage was enhanced in
Triptolide-treated LNCaP cells, and to a less degree, in Celastrol-
treated LNCaP cells (Fig. 2F). Again, lower levels of PARP
fragments were detectable in Celastrol or Triptolide-treated PC-3
cells (Fig. 2G). Altogether, these data demonstrated that
Triptolide, and to a less degree, Celastrol, induce apoptosis in
PCa cells associated with activation of caspase-3 and cleavage of
PARP.
Triptolide suppressed xenografted PC-3 tumor growth in
vivo
We observed that Triptolide can inhibit PCa cell proliferation
and induce cell apoptosis in vitro. To determine the efficacy of
Triptolide in vivo, we carried out xenograft study. PC-3 cells were
implanted subcutaneously in nude mice. When the tumors became
palpable (,100 mm
3), mice were treated intraperitonneally with
either a vehicle control or Triptolide at 0.4 mg/kg daily for 15
days. Tumor sizes and body weight were measured every three
days. As shown in Figure 3, the volume (Fig. 3A) and weight
(Fig. 3C) of xenograft tumors treated with Triptolide were
significantly smaller than those in the control group (Fig. 3D),
indicating that Triptolide has potent anti-tumor effect in vivo.
Meanwhile, there was no significant difference in body weight
between the treated and the control group (Fig. 3B), suggesting
that administered dose of Triptolide has no significant toxicity to
mice.
Triptolide down-regulated SENP1 expression in PCa cells
Since Triptolide inhibited PCa cell proliferation and induced
cells apoptosis in vitro, and suppressed xenografted tumor growth in
vivo, we were interested in the mechanisms underlying these anti-
tumor effects. Previous studies showed that SENP1 is over-
expressed in PCa cells and tumors samples [15]. SENP1 over-
expression in transgenic mice promotes the development of
malignant lesions in the prostate gland [15]. These data suggest
that over-expression of SENP1 mediates PCa development and
SENP1 could be a potential target for PCa therapy.
To investigate whether Triptolide regulates SENP1 expression,
firstly we analyzed SENP1 mRNA level by real-time PCR in
LNCaP and PC-3 cells treated with various doses of Triptolide or
Celastrol for 24 h, or treated with 0.1 mM Triptolide or Celastrol
for desired times. As shown in Figure 4A and 4B, Triptolide
significantly decreased SENP1 mRNA levels in both LNCaP and
PC-3 cells in dose-dependent and time-dependent manners.
Meanwhile, Celastrol also reduced SENP1 mRNA level following
a brief treatment at low doses. In contrast, at high doses and with
longer treatment time, Celastrol enhanced SENP1 mRNA level in
both treated PCa cell lines. To evaluate the efficacy of Triptolide-
induced down-regulation of SENP1 expression, we determined the
dose of Triptolide required to induce 50% decrease in SENP1
mRNA (IC50). Both LNCaP and PC-3 cells were treated with
more than 6 doses Triptolide for 24 h, as shown in Figure 4C,
Triptolide efficiently induced the decrease in SENP1 mRNA level
with IC50 value 0.07579 mM and 0.07071 mM for LNCaP and
PC-3 cells respectively. We further measured the SENP1 protein
level in PCa cells treated with Triptolide or Celastrol. Triptolide
was able to decrease the SENP1 protein level in both dose-
dependent (Fig. 4D, 4E) and time-dependent (Fig. 4F) manners. In
contrast, Celastrol did not significantly reduce SENP1 protein
level in treated PCa cells. These results are consistent with our
qRT-PCR results and indicate that Triptolide suppresses SENP1
expression in PCa cells at both mRNA and protein levels.
SENP1 plays an important role in SUMOylation processes. As
an isopeptidase, SENP1 deconjugates SUMO from SUMOylated
protein. A reduced SENP1 expression in Triptolide-treated PCa
cells would result in an enhanced cellular SUMOylation. To verify
this expectation, the cellular SUMOylation level in PC-3 cells
treated with 1 mM Triptolide or Celastrol for 24 h was detected by
Western blot using SUMO-1 antibody. Cells without treatment
but lysed in lysis buffer in the presence of 20 mM N-
ethylmaleimide (NEM), a potent inhibitor of deubiquitinating
enzymes and of SUMO hydrolase activity, was used a positive
control [20]. As shown in Figure 4G, compare to control,
Triptolide treatment significantly enhanced total SUMOylation
level. Interestingly, Celastrol also enhanced total SUMOylation
level, but with less efficiency compared to Triptolide, which could
result from its proteasome suppression activity. It was reported
that SUMOylation of some proteins, such as HIF1 [12] and PML
[21], promotes these proteins ubiquitin-dependent degradation. As
a proteasome inhibitor, Celastrol could suppress degradation of
these SUMOylated proteins and induce their accumulation. To
confirm this result, we performed similar experiments using
another SUMO-1 monoclonal antibody. The western blot results
showed that the levels of SUMO-1 heterodimers were increased in
Triptolide treated samples (Fig. S2A, S2B). We also found that the
level of SUMO-1 monomer was reduced in Triptolide treated
samples (Fig. S2C). This could result from either down-regulated
SENP1 expression, or the increase of SUMO-1 heterodimers.
Overall, Triptolide is able to negatively regulate SENP1 expres-
sion at both mRNA and protein levels, resulting in an enhanced
cellular SUMOylation level in PCa cells.
Triptolide suppressed androgen receptor (AR) expression
in LNCaP cells
AR plays an important role in normal prostate development
and maintenance, and in prostate cancer progression. Celastrol
was reported to suppress AR expression in LNCaP cells [1]. We
raised the question whether Triptolide inhibits AR expression and
AR-mediated transcription in PCa cells. We analyzed AR mRNA
level in LNCaP cells treated with various doses of Triptolide and
Celastrol for 24 h or with 0.1 mM Triptolide and Celastrol for
desired times by real-time PCR. As shown in Figure 5A and 5B,
experiments. * indicates P,0.05 (compared to control). (C) Effect of Triptolide on LNCaP cells. (D) Effect of Celastrol on LNCaP cells. (E) Effect of
Triptolide on PC-3 cells. (F) Effect of Celastrol on PC-3 cells. (G) and (H) PCa Cells were treated with indicated concentrations of Triptolide or Celastrol
and cells viability was determined by MTT assay. All assays were performed in triplicate, and data shown are mean 6 SD of four independent
experiments. (G) Effect of Triptolide and Celastrol on LNCaP cells. (H) Effect of Triptolide and Celastrol on PC-3 cells.
doi:10.1371/journal.pone.0037693.g001
Table 1. IC50 values.
Name Time (h) IC50 (mM) Cell
Celastrol 48 0.4881 PC-3
Triptolide 48 0.0203 PC-3
Celastrol 48 1.195 LNCaP
Triptolide 48 0.009754 LNCaP
doi:10.1371/journal.pone.0037693.t001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37693Figure 2. Triptolide and Celastrol induce apoptosis in PCa cells in vitro. (A) and (B) Fluorescence microscopy observation of Triptolide- and
Celastrol- induced apoptosis in LNCaP (A) and PC-3 (B) cells. After treatment with 1 mM Celastrol or Triptolide for 24 h, LNCaP and PC-3 cells were
incubated with AV-FITC (green) and PI (red). Representative bright field and fluorescent images are shown. (C) Flow cytometric detection of apoptosis
in LNCaP and PC-3 cells treated as above. Percentage of intact cells (AV2/PI2), early apoptotic cells (AV+/PI2), late apoptotic/necrotic cells (AV+/PI+)
and necrotic cells (AV2/PI+) are presented. (D) and (E) Western blot analysis of caspase-3 protein in Triptolide- or Celastrol-treated LNCaP (D) and PC-
3 (E) cells. Cells were treated with indicated concentrations of Triptolide or Celastrol for 24 h and subjected to analysis. Uncleaved caspase-3 and
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dependent and time-dependent manners. We further analyzed
the AR protein level in LNCaP cell treated with Triptolide, with
Celastrol-treated cells as positive control. As shown in Figure 5C
and 5D, Triptolide reduced AR protein expression in the same
manners as mRNA level. Since AR functions through binding to
androgen-response-elements (AREs) in the promoter region of
target genes and regulates these androgen response genes
transcription to induce cell proliferation [22], Triptolide-induced
suppression of AR expression could inhibit AR-mediated tran-
scription. To verify this hypothesis, expression of several AR
targets genes in AR-positive LNCaP cells treated with various
doses of Triptolide for 24 h was detected by qRT-PCR (Fig. 5E).
The expression of PSA, BARD1, Cdk1, Cdk2 and FKBP51,
known to be positively regulated by AR, were indeed suppressed.
These data suggest that Triptolide inhibited AR transcription
activity by suppressing AR expression. In addition to the AR target
genes, prostate-specific antigen (PSA) is an important biological
marker for the clinical diagnosis of human prostate cancer [23,24].
Therefore, we further detected PSA protein level in LNCaP cell
lysate and culture medium by chemiluminescence immunoassay
(CLIA). PSA protein level in LNCaP cells and that secreted into
medium were decreased following 1 mM Triptolide treatment
(Fig. 5F), while the same concentration of Celastrol showed less
suppressive effect on PSA. Overall, these results indicate that
Triptolide suppresses AR expression and induces AR-mediated
transcription inhibition.
Triptolide down-regulated c-Jun expression in PCa cells
Oncoprotein c-Jun which is often over-expressed in cancer cells
is involved in PCa transformation [25]. c-Jun is a major
component of the transcription factor AP-1 [26,27]. In addition,
c-Jun co-activates AR transcriptional activities, and SENP1
suppresses c-Jun expression [18]. In order to determine whether
Triptolide regulates c-Jun expression, we treated PCa cells with
various doses Triptolide or Celastrol for 24 h, or with 0.1 mM
Triptolide or Celastrol for desired times. As shown in Figure 6A–
6D, c-Jun expression, at mRNA and protein levels, was suppressed
by Triptolide in dose-dependent and time-dependent manners. In
cleaved products are indicated. a-tubulin was used as a loading control. (F) and (G) Western blot analysis of PARP and caspase-3 proteins in
Triptolide- or Celastrol-treated LNCaP (F) and PC-3 (G) cells. Cells were treated with 1 mM Triptolide or Celastrol for desired times. Uncleaved PARP and
caspase-3 and their cleaved products are indicated. a-tubulin was used as a loading control.
doi:10.1371/journal.pone.0037693.g002
Figure 3. Triptolide suppressed PC-3 tumor progression in mouse xenograft model. PC-3 cells (2610
6 per mouse) were injected into 5-
week-old nude mice. When solid tumors grew to about 100 mm
3, the mice were treated intraperitonneally with either a vehicle control or Triptolide
at 0.4 mg/kg daily for 15 days. Tumor sizes and body weight were measured every three days. (A) Effect of Triptolide on xenograft tumor volume. (B)
Effect of Triptolide on nude mice body weight. (C) Effect of Triptolide on xenograft tumor weight. (D) Image of xenograft tumor treated with or
without Triptolide.* indicates P,0.05 (compared to control).
doi:10.1371/journal.pone.0037693.g003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37693Figure 4. Triptolide down-regulated SENP1 expression in PCa cells. (A) Triptolide decreased SENP1 mRNA level in both LNCaP and PC-3 cells
in a dose-dependent manner. Cells were treated with indicated doses of Triptolide or Celastrol for 24 h before analysis. qRT-PCR were performed
using the specific primers for SENP1 and b-actin (used as an internal control). (B) Triptolide decreased SENP1 mRNA level in both LNCaP and PC-3 cells
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study the effect of Triptolide on activity of c-Jun, we analyzed the
c-Jun target genes expression by qRT-PCR. c-Jun target genes
Cyclin A2, Cyclin D1, ETV1 and p21, which are known to be up-
regulated by c-Jun were suppressed following Triptolide treatment
(Fig. 6F). These data indicate that Triptolide suppresses c-Jun
expression at mRNA and protein level and resultes in c-Jun
mediated transcription inhibition.
Down-regulation or over-expression of SENP1, c-Jun or
AR inhibited Triptolide anti-PCa efficacy
Since we observed that Triptolide suppressed SENP1 expres-
sion, enhanced cellular SUMOylation, inhibited AR and c-Jun
expression and suppressed AR/c-Jun-mediated transcription, we
asked whether Triptolide anti-PCa efficacy relies on SENP1, c-Jun
or AR expression in LNCaP and PC-3 cells. To answer this
question, firstly we knocked down SENP1, c-Jun or AR expression
by specific siRNA in LNCaP (with siRNA of SENP1, c-Jun or AR)
and PC-3 (with siRNA of SENP1 or c-Jun) cells. Twenty-four
hours after siRNA transfection, cells were treated with 100 nM
Triptolide or vehicle control for 48 h, the viable cells number was
counted then. Efficiency of siRNA againt SENP1, c-Jun and AR
were evaluated by Western blot (Fig. 7C). Interestingly, in the
absence of Triptolide treatment, silencing of SENP1, c-Jun or AR
in LNCaP cells reduced cellular viability (Fig. 7A). Similarly,
silencing of SENP1 or c-Jun in PC-3 cells also decreased cellular
viability (Fig. 7B). This observation may indicate that cytotoxicity
of Triptolide in PCa cells could result from Triptolide-induced
downregulation of SENP1, AR or c-Jun. In order to reveal the
effect of Triptolide on the SENP1, AR or c-Jun silenced cells, we
introduced the value of ‘the viability ratio’ which is obtained by
dividing the viable cell number of the Triptolide-treated group by
that of the control group without Triptolide-treatment. Interest-
ingly, knockdown of SENP1, c-Jun or AR appeared to increase
cells viability ratio under Triptolide treatment (Fig. 7A, 7B),
suggesting higher Triptolide resistance. We further checked the
effect of SENP1, c-Jun or AR over-expression on Triptolide anti-
PCa efficacy. PCa cells were transfected or co-transfected with
SENP1, c-Jun and AR expression plasmids (Fig. 7F). An irrelevant
protein EGFP was used as a negative control and a Triptolide
binding protein XPB was used as a positive control. 48 h after
transfection, cells were treated with Triptolide for another 48 h
and viable cells number was counted. Ectopic expression of these
proteins were evaluated by Western blot (Fig. 7F). As shown in
Fig. 7D–7E, ectopic expression of SENP1, c-Jun or AR
significantly increased PCa cells viability ratio under Triptolide
treatment, indicating that rescuing these three Triptolie down-
regulating proteins expression could inhibit Triptolide cell toxicity.
Furthermore, co-expression of these proteins conferred higher cells
viability ratio than respective individual expression, suggesting that
all these proteins are involved in Triptolide cytotoxity. In contrast,
over-expression of an irrelevant protein EGFP did not affect the
toxicity of Triptolide, which showed similar cells viability ratio
with empty vector control, suggesting that the effect of SENP1, c-
Jun or AR over-expression on Triptolide toxicity were indeed
resulted from their molecular function. Interestingly, ectopic
expression of SENP1, c-Jun or AR showed similar effect under
Triptolide treatment as XPB over-expression did. It was reported
that Triptolide binds XPB to induce RNA polymerase II–
mediated transcription inhibition, suggesting that down-regulation
of SENP1, c-Jun and AR expression are important for Triptolide
effect. We noticed that ectopic expression of these proteins
including EGFP mildly decreased cells number, especially in PC-3
cell line. This may be due to the robust expression of these proteins
affect other protein expression. Nevertheless, this effect did not
influence Triptolide activity since ectopic expression of EGFP
showed similar cell viability ratio with vector control under
Triptolide treatment, and ectopic expression or co-expression of
SENP1, c-Jun or AR induced cell number increase in Triptolide
treatment groups in LNCaP cells comparing with vector control.
Taken together, down-regulation or over-expression of SENP1, c-
Jun or AR appears to significantly inhibit Triptolide anti-PCa
toxicity, indicating that down-regulation of SENP1, c-Jun or AR
by Tritpolide is important for Tritplode activity, suggesting these
proteins are key targets of Triptolide for its’ anti-PCa effect.
Discussion
The Chinese herb Tripterygium wilfordii Hook F has been used for
centuries in traditional Chinese medicine for treating fever, chills,
edema and carbuncle. Recently, this herb has attracted intensive
attention from researcher worldwide for its potent efficacy on
many diseases. More than 100 small active compounds have been
extracted from this herb. The diterpenoid epoxide Triptolide and
the quinine triterpene Celastrol, two main bioactive components
of Tripterygium wilfordii Hook F, exhibit anti-tumor activity. They
have been shown to suppress cell proliferation and induce
apoptosis in many types of cancer including breast cancer
[3,28], pancreas cancer [4,29], prostate cancer [1,5,30], either in
cell culture assay or in xenografted tumor assay. Celastrol has been
identified as a natural 26 s proteasomal inhibitor that has great
potential for PCa therapy [1]. But the efficacy of Triptolide on
human PCa has been less studied. In this study, we demonstrated
that Triptolide suppressed proliferation and induced apoptosis in
two PCa cell lines: the androgen-dependent LNCap cells and
androgen-independent PC-3 cells. This is in consistent with the
findings of Li et al [31]. Furthermore, Triptolide suppressed
xenografted PC-3 tumor progression in nude mice. Based on cell
viability assay and IC50 value, Triptolide exhibited more potent
effect than Celastrol on PCa cells and had antiproliferation activity
at a nanomolar grade. It was reported that Triptolide inhibits
proliferation of all 60 cancer cell lines in US National Cancer
Institute with average IC50 value at 12 nM [32]. Triptolide also
reveals a antiproliferative activity on a panel of 12 different cell
lines with IC50 values in the 3–70 nM range [33]. All these data
suggest that Triptolide is a potent natural anti-tumor compound
and has potential for PCa therapy.
Triptolide has been shown to induce apoptosis in many cancer
cells in vitro or in vivo. In this study, we demonstrated that both
in a time-dependent manner. Cells were treated with 0.1 mM Triptolide or Celastrol for indicated times, SENP1 and b-actin mRNA levels were
determined by qRT-PCR. (C) Effect of Triptolide on SENP1 mRNA level in PCa cells. IC50 was shown as calculated by Prism 5.04. (D) and (E) Triptolide
decreased SENP1 protein level in LNCaP (D) and PC-3 (E) in a dose-dependent manner. Cells were treated with indicated doses of Triptolide or
Celastrol for 24 h before Western blot analysis. a-tubulin was used as a loading control. (F) Triptolide decreased SENP1 protein level in PCa cells in a
time-dependent manner. PC-3 cells were treated with 1 mM Triptolide for indicated time before Western blot analysis. b-actin was used as a loading
control. (G) Triptolide enhanced cellular SUMOylation in PC-3 cells. PC-3 cells were treated with 1 mM Triptolide or Celastrol for 24 h before Western
blot analysis using SUMO-1 antibody. NEM was used as a positive control for a SUMO protease inhibitor.
doi:10.1371/journal.pone.0037693.g004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37693Figure 5. Triptolide down-regulated AR expression in LNCaP cells. (A) Triptolide decreased AR mRNA level in LNCaP cells in a dose-
dependent manner. LNCaP cells were treated with indicated doses of Triptolide for 24 h before analysis. qRT-PCR was performed using the specific
primers for AR and b-actin. (B) Triptolide decreased AR mRNA level in LNCaP cells in a time-dependent manner. LNCaP cells were treated with 0.1 mM
Triptolide for indicated times before analysis. (C) Triptolide and Celastrol decreased AR protein level in LNCaP cells in a dose-dependent manner.
LNCaP cells were treated with indicated doses of Triptolide or Celastrol for 24 h before Western blot analysis. a-tubulin was used as a loading control.
(D) Triptolide decreased AR protein level in LNCaP cells in a time-dependent manner. LNCaP cells were treated with 0.1 mM Triptolide for indicated
times before Western blot analysis. a-tubulin was used as a loading control. (E) Triptolide decreased AR target genes expression in LNCaP cells. LNCaP
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37693cells were treated with indicated doses of Triptolide for 24 h before qRT-PCR analysis using respective specific primers. (F) Triptolide inhibited PSA
protein level in LNCaP cells. LNCaP cells were treated with Triptolide or Celastrol for 24 h or 48 h. Aliquots of medium and cell lysis from the treated
cells were collected and the total PSA level was measured by CLIA.
doi:10.1371/journal.pone.0037693.g005
Figure 6. Triptolide down-regulated c-Jun expression in PCa cells. (A) Triptolide decreased c-Jun mRNA level in LNCaP and PC-3 cells in a
dose-dependent manner. Cells were treated with indicated dose of Triptolide for 24 h before RNA extraction and qRT-PCR using the specific primers
for c-Jun and b-actin. (B) Triptolide decreased c-Jun mRNA level in LNCaP and PC-3 cells in a time-dependent manner. Cells were treated with 0.1 mM
Triptolide for indicated time before RNA extraction and qRT-PCR. (C) and (D) Triptolide decreased c-Jun protein level in LNCaP (C) and PC-3 (D) cells in
a dose-dependent manner. Cells were treated with indicated dose of Triptolide or Celastrol for 24 h before Western blot analysis. a-tubulin was used
as a loading control. (E) Triptolide decreased c-Jun protein level in LNCaP cells in a time-dependent manner. LNCaP cells were treated with 0.1 mM
Triptolide for indicated time before Western blot analysis. a-tubulin was used as a loading control. (F) Triptolide inhibited c-Jun target genes
expression in LNCaP cells. LNCaP cells were treated with indicated concentration of Triptolide for 24 h before qRT-PCR analysis of c-Jun target genes
using respective specific primers.
doi:10.1371/journal.pone.0037693.g006
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PCa cell lines tested associated with caspase-3 activation and
PARP cleavage. The AR-positive cell line LNCaP seems more
sensitive to these two compounds than AR-negative cell line PC-3.
Wang et al [34] reported that Triptolide induces apoptosis in
cervical adenocarcinoma cells HeLa and pancreatic carcinoma
cells PANC-1, associated with activation of caspase-8/9/3 and
cleavage of PARP and Bid. Wan et al [35] found that Triptolide
induces apoptosis in promyelocytic leukemia cells HL-60 with
concomitant DNA fragmentation, S phase cell cycle arrest,
Figure 7. Down-regulation or over-expression of SENP1, c-Jun or AR inhibited Triptolide anti-PCa efficacy. (A) and (B) Down-regulation
of SENP1, c-Jun or AR expression increased cell viability upon Triptolide treatment. LNCaP and PC-3 cells were transfected with specific siRNA against
SENP1, c-Jun and AR. 24 h after transfection, the transfected cells were treated with 100 nM triptolide or vehicle control for 48 h, then the viable cell
number was counted in each treatment. (A) Effect of knockdown SENP1, c-Jun and AR on Triptolide efficacy in LNCaP cell. Left chart shows the viable
cell number in each treatment. Right chart shows the viability ratio. (B) Effect of knockdown SENP1 and c-Jun on Triptolide efficacy in PC-3 cell. *
indicates P,0.05 (compared to control). (C) Down-regulation of SENP1, c-Jun and AR protein levels by siRNA in (A) and (B). (D) and (E) Over-
expression of SENP1, c-Jun and AR rescued cell viability upon Triptolide treatment. PCa cells were transfected or cotransfected with 800 ng SENP1, c-
Jun and AR expression plasmids DNA as indicated. EGFP protein was used as a negative control and the Triptolide binding protein XPB was used as a
positive control. Empty vector was used as blank control and to keep the total amount of plasmids DNA equal in each well. 48 h after transfection,
cells were treated with Triptolide for another 48 h and viable cell number were counted. (D) Effect of ectopic expression or coexpression of SENP1, c-
Jun and AR on Triptolide efficacy in LNCaP cells. (E) Effect of ectopic expression or coexpression of SENP1 and c-Jun on Triptolide efficacy in PC-3 cells.
* indicates P,0.05 (compared to control). (F) Ectopic expression or coexpression of SENP1, c-Jun and AR in PCa cells evaluated by Western blot using
anti-Flag and anti-HA antibodies.
doi:10.1371/journal.pone.0037693.g007
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results indicate that mitochondria-mediated pathway and caspase
cascade are involved in Triptolide-induced apoptosis. However,
Tan et al [36] reported that potent caspase inhibitor zVAD-fmk
causes significant reduction of focal adhesion kinase (FAK) and
PARP cleavage, but fails to prevent Triptolide-induced cell death
in breast cancer cells MCF-7, suggesting that Triptolide-induced
apoptosis is probably mediated through multiple mechanisms and
pathways in addition to mitochondria-mediated pathway and
caspase cascade. It seems that Triptolide induces apoptosis
regardless of p53 status of target cells as both LNCap (p53 intact)
and PC-3 (p53 deficient) cells are responsive to Triptolide. The
previous reported studies have shown that Triptolide induces
apoptosis in these PCa cells without affecting p53 expression [31],
and that Triptolide may function differently in various cells with
different p53 status [37], pointing the potential efficacy of
Triptolide on tumor types with p53 mutation/deletion. Taken
together, these data indicate that Triptolide is capable to trigger
massive apoptosis in cancer cells through multiple mechanisms
and pathways.
Epigenetic alterations play a key role in cancerogenesis and
progression [38]. These alterations include not only DNA
methylation and covalent histone modification, but also nonhis-
tone protein postmodification like phosphorylation, acetylation,
ubiquitylation and SUMOylation, the altered expression of
enzymes of these postmodification and the imbalance of these
reversible covalent modifications. Since epigenetic aberrations are
reversible and can be restored to their normal state, epigenetic
therapy to reduce the tumorigenicity promises a novel approach
against cancer and is becoming attractive [39–41]. For example,
successful use of bortezomib, a 26S proteasome inhibitor, for the
treatment of multiple myeloma is based on its targeting in
ubiquitin/proteasome-mediated pathways [42–44]. The therapeu-
tic efficacy of arsenic trioxide in acute promyelocytic leukemia is
dependent on the SUMOylation of PML–RARa oncoprotein
[21]. These evidences indicate that ubiquitination and SUMOyla-
tion play important roles in human cancer progression and could
be effective therapy targets. SUMOylation has been linked to
tumorigenesis and cancer metastasis [45,46]. Altered expression of
SENPs has been detected in several carcinomas [47]. Balance of
SUMOylation and DeSUMOylation is important for cell to
maintain normal physiological process. The imbalance perturbs
cell fate and initiate cancer development [47]. SENP1, one of
SUMO-specific protease which processes the pro-SUMO to
mature SUMO and deconjugates the modified proteins is elevated
in PCa and plays a regulatory role in PCa development [15].
Although the mechanism underlining the function of overex-
pressed SENP1 in PCa progression is not clear, SENP1 has been
demonstrated to promote many proteins activities playing roles in
PCa development. SENP1 reverses the ligand-induced SUMOyla-
tion of AR and promotes AR-dependent transcription [48].
SENP1 also promotes AR-mediated transcription via its deSU-
MOylation on HDAC1 which inhibits the HDAC1 deacetylase
activity and transcription suppression ability [17]. SENP1
enhances the c-Jun dependent transcription via deSUMOylation
of the CRD1 domain of p300, releasing the cis repression of CRD1
domain of p300 [18]. SENP1 is essential for stabilization of
hypoxia inducible factor 1 (HIF1a) through its deSUMOylation
during the hypoxia-induced process [12]. SENP1 is also essential
in endothelial cells as a positive regulator of hypoxia-driven VEGF
production and angiogenesis [49]. In the present study, we
demonstrated that Triptolide significantly down-regulates SENP1
expression at both mRNA and protein levels and results in an
enhanced cellular SUMOylation in PCa cells. The potent efficacy
of Triptolide on PCa may be mediated by the down-regulation of
SENP1 expression and restoration of cellular SUMOylation level.
We observed that Triptolide suppressed AR expression at
mRNA and protein levels and inhibited AR-mediated transcrip-
tion in AR-positive LNCaP cells. Androgens are critical for the
normal prostate development and AR transduces the androgen
signals to regulate the network of androgen response genes [50].
On the other hand, androgens are involved in PCa development
under pathological situation. The androgen ablation therapy
remains a standard treatment for advanced PCa. Most patients
show positive response to the treatment but nearly 20% cases
develop to hormone-refractory (HR) PCa in 1–2 years. Once the
cancer progresses to HRPC stage, the PCa turns more malignant
with poor prognostics. Throughout prostate cancer progression
including HRPC, AR overexpresses or undergoes mutations
[51,52]. Most identified mutated AR in PCa still retain their
transcription activities and are transcriptionally active in response
to ligands in addition to androgens. AR co-activators such as SRC-
1, SRC-3, TIF-2 [53,54] which could enhance the transcriptional
activity of AR and contribute to the sensitization of AR to low
levels of androgen concentrations are also elevated in prostate
cancer. These observations suggest that PCa may result from
dysregulation of AR activity, pointing that AR could be an
important target for PCa therapy. Therefore, it is highly probable
that Triptolide inhibits PCa proliferation via suppression of AR
expression and consequent break of androgen response network
functions. That explains why AR positive LNCaP cells are more
sensitive to Triptolide than AR-negative PC-3 cells. Interestingly,
SENP1 modulates the AR transcriptional activities via its
deSUMOylation on AR and HDAC1 [17]. A positive feedback
loop exists between AR and SENP1 in which SENP1 enhances the
AR-dependant transcription, while AR potentiates the SENP1
expression by directly binding to the SENP1 promoter [55].
Disruption of this loop significantly blunts proliferation of
androgen-dependent PCa cells [55]. Triptolide may disturb the
AR and SENP1 loop by suppressing SENP1 and AR expression
and consequently inhibiting AR-mediated transcription.
We further demonstrated that Triptolide suppressed c-Jun
expression at mRNA and protein levels and c-Jun mediated
transcription in PCa cells. c-Jun, in combination with Fos
subfamily proteins, forms the early response transcription factor
AP-1. AP-1 regulates target genes expression through binding to
the AP-1 element in the promoter of these genes that involved in
various cellular events including development, cellular prolifera-
tion, differentiation, transformation, inflammation, apoptosis and
cellular migration [56]. Plenty of evidence indicate that c-Jun is a
bona fide oncoprotein. c-Jun was found highly expressed in many
types cancers such as sarcomas [57], classical Hodgkin’s disease
and anaplastic large cell lymphoma (ALCL) [58], in which c-Jun
promotes cancer cell proliferation and suppresses apoptosis. c-Jun
is elevated in PCa associated with cellular proliferation and
invasion [25]. In addition, c-Jun acts as an AR co-activator to
stimulate AR transactivation by mediating receptor dimerization
and subsequent DNA binding [25]. Since the important implica-
tion of c-Jun in carcinogenesis and tumor progression, it could be a
novel target in cancer treatment. It is highly possible that
Triptolide inhibits PCa cell proliferation through down regulation
of c-Jun expression and consequent inhibition of c-Jun and AP-1
mediated transcription. The AR-mediated transcription suppres-
sion may be partially caused via Triptolide-induced inhibition of c-
Jun co-activation. Analysis of c-Jun target genes expression showed
the c-Jun mediated transcription was inhibited by Triptolide as a
result of c-Jun expression suppression. The Triptolide-induced
suppression of SENP1 expression may also involve in this process
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deSUMOylation of the CRD1 domain of p300 [18].
In our study, Triptolide shows potent efficacy in suppressing
PCa cell proliferation and in inducing apoptosis. We observed that
Triptolide down-regulates SENP1, c-Jun and AR expression
which are over-expressed in PCa and play a pro-proliferation
role. We assume that Triptolide anti-PCa effect could be through
down-regulating expression of SENP1, c-Jun and AR. The
knockdown and rescue experiments confirm our hypothesis. We
found that down-regulation of SENP1, c-Jun or AR expression
suppress PCa cell viability, which consist with previous reports that
SENP1, c-Jun and AR have pro-proliferation roles in PCa and
further suggest that Triptolide anti-PCa effect could be through
down-regulation of SENP1, c-Jun and AR expression. Triptolide
treatment of PCa cells with silenced SENP1, c-Jun or AR further
decreased viable cells while the viability ratios were increased. It is
possible that knockdown of SNEP1, c-Jun or AR in PCa cells
could dilute targets for Triptolide action. Since Triptolide further
decreases cell proliferation in these proteins knockdown PCa cells,
which suggests that there could be other genes or proteins involved
in Tiptolide function. Over-expression experiments also support
above conclusion. Ectopic expression of SENP1, c-Jun or AR
increase the viability ratio in Triptolide treated PCa cells, as does
the Triptolide binding protein XPB over-expression. Furthermore,
co-expression of SENP1, c-Jun and AR induces higher cell viablity
ratio. All data indicate that SENP1, c-Jun and AR are potential
targets of Triptolide, and down-regulation of these proteins is
important for Triptolide anti-PCa toxicity. We notice that
individual over-expression or co-expression of SENP1, c-Jun or
AR do not suppress completely Triptolide effect. This could result
from the possibility that Triptolide suppresses expression of
SENP1, c-Jun or AR down-stream target genes or proteins, which
disturbs action of over-expressed SENP1, c-Jun and AR. However,
we could not exclude that other genes or proteins could be
involved in Triptolide induced cell death.
Triptolide suppresses expression of many genes or proteins in
treated cells, including p53, NF-kB, Bcl-2, Mcl-1 [59]. Our study
allows adding three new proteins, SENP1, AR and c-Jun, to the
list. Understanding the mechanisms underlying these regulations is
of major interest. Based on our data and others studies, we propose
that Triptolide suppresses PCa progression through multiple
pathways (Fig. 8). Triptolide could inhibit SENP1 transcription
and decreases SENP1 mRNA and protein levels that are elevated
in PCa. Consequently, the cellular SUMOylation is enhanced
which could restore the balance of SUMOylation and deSU-
MOylation, and suppress the functions of some key proteins
involved in PCa progression. For example, suppression of SENP1
expression and decrease activity of deSUMOylation on AR and
HDAC1 in PCa enhance AR SUMOylation and deacetylation by
HDAC1, leading to inhibition of AR-mediated transcription. c-
Jun mediated transcription is inhibited by the cis repression of
CRD1 domain of p300 which could be released by SENP1-
mediated deSUMOylation of CRD1 domain. Triptolide could
inhibit directly AR expression, inducing suppression of AR
mediated transcription. AR down-regulation also inhibits SENP1
expression, enhancing the cellular SUMOylation activities.
Triptolide could inhibit directly c-Jun expression to reduce AP-1
and c-Jun mediated transcription. The non-transcriptional func-
tion of c-Jun as co-activator also was suppressed. Furthermore,
Triptolide could influence other genes expression or target other
proteins to disturb these genes or proteins’ abnormal functions in
PCa. As a result, inhibition of AR and c-Jun mediated
transcription, suppression of other targets functions by SENP1
deSUMOylation and interruption of other important molecular
functions contribute to inhibit PCa proliferation and progression,
and to facilitate apoptosis.
The reason how Triptolide suppresses many genes and proteins
expression remains unknown. It’s reported that Triptolide could
bind a 90 kD unknown nuclear protein [60], which is revealed to
be a subunit of the transcription factor TFIIH XPB [61].
Triptolide covalently binds to XPB and inhibits its DNA-
dependent ATPase activity, leading to the inhibition of RNA
polymerase II–mediated transcription. Triptolide was also found
to induce phosphorylation of Rpb1, another subunit of RNA
polymerase II, and subsequent proteasome-dependent degrada-
tion, which results in a global transcription inhibition [62]. Both
XPB and Rpb1 as targets of Triptolide may account for its
suppression effect on expression of many genes and its high
efficacy on cancer cells. Further studies are required to determine
whether Triptolide down-regulates SENP1, c-Jun and AR through
targeting XPB and Rpb1.
In summary, our study showed that Triptolide, an active
component extracted from Chinese medicinal herb, is an effective
agent against prostate cancer. Its anti-tumor activity may be
attributed to mechanisms involving down-regulation of SENP1
that restores SUMOylation and deSUMOyaltion balance and
negative regulation of AR and c-Jun expression that inhibits the
AR and c-Jun mediated transcription in PCa.
Materials and Methods
Ethics statement
This study was approved by The Ethics Committee for Animal
Experiments of the Fourth Military Medical University (Permit
Number: 11004) and the experimental protocol was carried out in
strict accordance with the institutional guidelines and the criteria
outlined in the ‘‘Guide for Care and Use of Laboratory Animals’’.
All surgery was performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering.
Reagents
Purified Celastrol (.98%) and Triptolide (.98%) were
purchased from p-p Technologies, Inc (Shenzhen, China) or
Sigma-Aldrich (C0869 & T3652), which were dissolved in DMSO
(Wolsen) at a stock concentration of 50 mM and stored at 4uC.
Trypan blue was from Sigma-Aldrich. Thiazolyl Blue Tetrazolium
Bromide (MTT, M6494), Vybrant Apoptosis Assay Kit #3
(V13242), Trizol Reagent and Lipofectamine
TM LTX with Plus
TM
Reagent were obtained from Invitrogen. High-Capacity cDNA
Reverse Transcription Kits was supplied by Applied Biosystems.
SYBRH PrimeScript
TM RT-PCR Kit II was from TaKaRa
(Dalian, China). DharmaFECTH 2 transfection reagent
(T200201) was from Dharmacon RNAi Technologies. Antibodies
for SENP1 (sc-46634), AR (sc-7305), a-tubulin (sc-5286), b-actin
(C4), SUMO-1 (sc-5308) were from Santa Cruz Biotechnology.
Another SENP1 antibody (ab58417) was from Abcam. Antibodies
for Caspase-3 (#9662), PARP (#9532) and c-Jun (#9165) were
from Cell Signaling Technology. Antibodies for Flag (CW0090)
and HA (CW0260) tags were from CWBIO (Beijing, China).
Rabbit polyclonal SUMO-1 antibody was generated by our
laboratory using recombinant SUMO-1according to standard
protocol. Secondary antibodies for goat anti-mouse IR Dye 680
(926–32220) and 800 cw (926–32210), donkey anti-goat IR Dye
680 (926–32224) and 800 cw (926–32214), and goat anti-rabbit IR
Dye 680 (926–32221) and 800 cw (926–32211) were from LI-
COR Biosciences.
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ON-TARGETplus SMARTpool siRNAs for human SENP1 (L-
006357-00), human c-Jun (L-003268-00), human AR (L-003400-
00) and Non-targeting control siRNA were purchased from
Dharmacon RNAi Technologies. Flag-EGFP, Flag-SENP1, Flag-
c-Jun and Flag-XPB were made by standard cloning method.
SENP1, c-Jun and XPB coding DNA fragments without ATG
were amplified by PCR using the cDNA reverse transcription from
LNCaP total mRNA as template. EGFP coding fragment was
cloned from pEGFPN1. Cloned fragments were subcloned into
BamHI and EcoRI digested pcDNA3 vector with a Flag tag. The
sequences of constructs were confirmed by DNA sequencing. The
AR expression plasmid Psl2-HA-AR was a gift from Dr.
Guangchao Sui (Wake Forest University).
Cell culture
LNCaP and PC-3 cells, purchased from Institute of Basic
Medical Sciences Chinese Academy of Medical Sciences, were
maintained in RPMI1640 (GIBCO) supplemented with 10% fetal
bovine serum, 100 units/ml of penicillin and streptomycin, and
incubated at 37uC with 5% CO2.
Cell proliferation assay and viability assay
LNCaP and PC-3 cells were plated in 24-well plate at a density
of 1610
4 per well and cultured until attachment, then treated with
various doses of Triptolide or Celastrol, using DMSO as negative
control and no treatment as blank control. Cells were gently
trypsinized and staining with trypan blue dye. The viable cells
were counted using cell counting chamber every 24 h for 7 days.
For viability assay, 5610
3 LNCaP or 3610
3 PC-3 cells per well
were plated in 96-well plate and cultured until attachment, then
treated with various doses of Triptolide or Celastrol for 48 h, using
DMSO as negative control. After adding 100 ml medium
containing 10 ml MTT solution (5 mg/ml stock in PBS) per well,
the plates were incubated at 37uC with 5% CO2 for 4 h.
Aspirating the medium, the crystals formed in each well were
dissolved in 100 mL DMSO and mix on Shaker for 1 min. The
absorbance of each well was measured on a Multilabel counter
(PerkinElmer Victor
3TM 1420) at 595 nm. Each treatment was
performed in triplicate and experiments were repeated over 4
times. Data were expressed as percentage of growth inhibition as
follows: relative cell viability=(A595 (treated)-A595 (blank))/(A595
(control)-A595 (blank)). 50% inhibitory concentration (IC50) was
calculated from viability assay data with GraphPad Prism 5.04
(GraphPad Software, Inc) using a sigmoidal dose-reponse nonlin-
ear regression analysis.
Transient transfection and treatment
LNCaP or PC-3 cells were plated in 6- or 12-well plate and
cultured until attachment. To knockdown SENP1, c-Jun or AR
Figure 8. Hypothetic mechanisms of anti-PCa effects of Triptolide. Triptolide suppresses SENP1, AR and c-Jun expression, induces
restoration of SUMOylation/deSUMOyaltion balance, inhibitions of the AR and c-Jun mediated transcription, which may all contribute to the anti-PCa
effect of Triptolide. Other genes or proteins may involve in mechanism of Triptolide effect (see Discussion for detail).
doi:10.1371/journal.pone.0037693.g008
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fected into PCa cells using DharmaFECTH 2 transfection reagent
according to the manufacturer’s instructions. Non-targeting
siRNA was used as control. For overexpression, 800 ng each
expression plasmid DNA was transfected or co-transfected into
PCa cells using Lipofectamine
TM LTX with Plus
TM Reagent.
Empty vector was used as blank control and to keep the total
amount of plasmids DNA equal in each well. The plasmids
expression irrelevant protein EGFP and Triptolide binding protein
XPB were used as negative and positive control, respectively. 48 h
after transfection, cells were treated with Triptolide for another
48 h. After stained with trypan blue, viable cells were counted
using cellometer Auto T4 automated cell counter.
Apoptosis analysis
1.5610
5 LNCaP or 1610
5 PC-3 cells per well were cultured in
6-well plate in which coverslips were plated. After attachment,
cells were treated with 1 mM Triptolide or Celastrol for 24 h.
Annexin V (AV)/propidium iodide (PI) co-labeling was performed
using the Vybrant Apoptosis Assay Kit #3 according to the
manufacturer’s instructions. The apoptotic cells were analyzed by
inverted fluorescence microscopy (Leuca DM IRM) or by flow
cytometry (FACSCalibur, Becton Dickinson) using FITC signal
detector (FL1) and phycoerythrin emission signal detector (FL2).
Data analysis was performed using Expo32 (version 1.2) software.
Chemiluminescence Immumo-Assay (CLIA)
LNCaP cells were cultured in 6-well plate at a density of 1610
5
cells per well and then treated with 1 mM Triptolide or Celastrol
for 24 h or 48 h. Aliquots of medium and cell lysate from the
treated cells were collected to measure the total PSA level on a
chemiluminescence apparatus (Roche Cobas E601) according to
protocol of CLIA.
Real-time PCR
LNCaP or PC-3 cells were cultured in 6-well plate and then
treated with various doses of Triptolide or Celastrol for 24 h or
with 0.1 mM Triptolide and Celastrol for desired time points.
RNA was isolated from treated cell using Trizol Reagent following
the manufacturer’s instructions. 500 ng total RNA was reverse
transcribed to cDNA using High-Capacity cDNA Reverse
Transcription Kits. The real-time PCR were performed on the
Bio-Rad CFX 96 Real-time PCR system using SYBRH Prime-
Script
TM RT-PCR Kit II and specific primers (Figure S3). mRNA
level of each gene were normalized to b-actin with DDCT method
using Bio-Rad CFX Manager V1.1.308.1111 software. The
relative mRNA level was calculated by dividing the normalized
each gene expression of treated cells with untreated control
sample.
Western blot analysis
LNCaP or PC-3 cells were treated with various doses of
Triptolide or Celastrol for 24 h or with 0.1 mM Triptolide or
Celastrol for desired times. Cell were trypsinized and washed with
cold PBS. Cell pellets were lysed with lysis buffer (50 mM Tris
[pH 7.5], 5 mM EDTA, 0.1% NP-40, 300 mM NaCl, with freshly
added 0.5 mM phenylmethylsulfonyl fluoride and 16 Roche
protease inhibitors cocktail solution) and incubated on ice for
30 minutes with gentle shake or with M-PER protein extraction
solution according to the instructions (Thermo Scientific,
#78501). Protein samples were separated by 12% SDS-polyacryl-
amide gel electrophoresis and electrotransferred to nitrocellulose
membrane. Protein blots were probed with an appropriate
primary antibody and a secondary antibody (IRDye, LI-COR)
and then analyzed by quantitative immunoblot using an Odyssey
Infrared Imaging System (LI-COR). a-tubulin or b-actin was used
as loading control.
Mouse xenograft assay
5-week-old male nude immunodeficient mice (NCRNU-M)
were purchased from Animal Research Center of the Fourth
Military Medical University (Xi’an, Shaanxi, China) and main-
tained in a standard environment. The mice were allowed to
acclimatize for at least 1 week before experiments. PC-3 cells
(2610
6) suspended in 0.1 mL of serum-free RPMI 1640 were
inoculated s.c. in the left flank of each mouse. When tumor volume
reached 100 mm
3, mice were divided randomly into control and
treatment groups. Mice in treatment group were injected with
Triptolide at 0.4 mg/kg daily for 15 days while control mice were
injected with vehicle (DMSO). Tumor sizes were measured using
calipers and their volumes were calculated using a standard
formula: width
26length/2, and body weight was measured every
three days. The xenograft tissues were collected immediately after
the animals were sacrificed and stored at 280uC for further study.
Statistical analysis
Results were expressed as the mean 6 SD. Student’s t test was
applied to evaluate the differences between treated and control
groups. For all the tests, the level of significance was set at P,0.05.
Supporting Information
Figure S1 Chart for the results from Figure 2C. After
treatment with Triptolide or Celastrol, LNCaP cells (A) and PC-3
cells (B) were stained with AV/PI and analyzed by flow cytometry.
Percentages of viable cells (AV2/PI2), early apoptotic cells
(AV+/PI2) and late apoptotic/necrotic cells (AV+/PI+) are
presented.
(TIF)
Figure S2 Triptolide enhanced cellular SUMOylation in
PCa cells. (A) and (B) Triptolide enhanced SUMO-1 heterodi-
mers level in PCa cells. PCa cells were treated with 1 mM
Triptolide or Celastrol for 24 h, Cell pellets were lysed in lysis
buffer with 20 mM NEM. Western blot were performed using a
SUMO-1 monoclonal antibody. (A) Triptolide enhanced SUMO-
1 heterodimers levels in PC-3 cells. (B) Triptolide enhanced
SUMO-1 heterodimers levels in LNCaP cells. (C) Triptolide
decreased SUMO-1 monomer level in LNCaP cells. LNCaP cells
were treated with 1 mM Triptolide or Celastrol for 24 h, Cell
pellets were lysed in normal lysis buffer. Western blot were
performed using a SUMO-1 monoclonal antibody.
(TIF)
Figure S3 Primers for plasmids construction and Real-
time PCR. Specific primers used for SENP1, c-Jun, XPB and
EGFP expression plasmids construction or analysis of SENP1, AR,
c-Jun, and AR/c-Jun target genes mRNA levels in Triptolide- or
Celastrol-treated PCa cells by Real-time PCR.
(TIF)
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